In this article, we will introduce a potent humanized IgG4k monoclonal antibody against programmed death-1 (PD-1) Geptanolimab. As a result, Geptanolimab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. As a result, Geptanolimab (CBT-501) has highly specific binding to PD-1 of humans (KD=505 pM) and cynomolgus (KD=7.2 nM).

ICIs primarily target PD-1/PD-L1. Moreover, ICIs and anti-PD-1 antibodies have become the main component of cancer therapy. PD-1/PD-L1 are immune-checkpoint molecules that inhibit the priming phase, this phase is related to the activation of antigen-presenting cells and T cells. It also has effects on the effector phase (direct damage to cancer cells) of the cancer-immunity cycle.

Geptanolimab enhances human T-cell activation in the Mix Lymphocyte Reaction (MLR), increasing the release of IL-2 and INF-γ.

Alveolar soft part sarcoma (ASPS) is a rare and distinctive subtype. Additionally,  It accounts for approximately 0.8% of all malignancies. ICIs exhibit encouraging effects in patients with ASPS. Besides, Geptanolimab (GB226) is clinically active (NCT03374007). in patients with unresectable, recurrent, or metastatic alveolar soft part sarcoma (ASPS).

As a potent anti-PD-1 antibody. Geptanolimab has the potential for multiple solid/non-solid tumor indications, both as a monotherapy and in combinations.

A combination of anti-VEGFR and anti-PD-1/L1 may synergize with each other and lead to better anti-tumor efficacy. Besides, Geptanolimab plus Fruquintinib (a VEGFR inhibitor) exhibits manageable safety profiles and encourages anti-tumor activity in mCRC patients (Clinical trial information: NCT03977090).
Peripheral T cell lymphoma (PTCL) is a rare disease. And recent approved drugs for PTCL provide limited clinical benefit. Furthermore, Geptanolimab (GB226), as an anti-programmed cell death 1 (PD-1) antibody, in patients with R/R PTCL(NCT03502629).
According to the results of the phase 2 multicenter trial presented at the virtual American Association for Cancer Research Annual Meeting. Geptanolimab appeared effective and safe for patients with relapsed or refractory peripheral T-cell lymphoma.

In conclusion, Geptanolimab is a potent anti-PD-1/L1 antibody for tumor research.


[1]. Clin Cancer Res. 2020 Dec 15;26(24):6445-6452.
[2]. Qing Z, et, al. Journal of Clinical Oncology. 2017;35 (7_suppl):108-108.